VELO3D announces Assure™ Quality Assurance and Control System for 3D metal printing and Stratasys Direct Manufacturing as First Customer of Assure
5.11.2019 18:00:00 EET | Business Wire | Press release
VELO3D, an innovator in metal Additive Manufacturing (AM) has announced the release and availability of the VELO3D Assure™ Quality Assurance and Control System for its Sapphire® 3D metal printers. Stratasys Direct Manufacturing, a subsidiary of Stratasys, Ltd. (NASDAQ: SSYS) and one of the largest providers of additive (3D printing) and conventional manufacturing services in North America, is the first customer to implement Assure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105005695/en/
VELO3D’s Assure™ quality control dashboard enables engineers to track the quality and progress of Sapphire® machines in real-time. (Graphic: Business Wire)
Assure provides substantiation of part quality needed for volume production. It detects process anomalies, flags them, and highlights the corrective actions required so errors are not repeated. Through real-time, multi-sensor, physics-based detection algorithms, Assure delivers unprecedented traceability of part quality and flags process anomalies as soon as they occur. This decreases variation and provides comprehensive documentation to fast-track printed-part validation.
“Assure is a revolutionary quality-control system, an inherent part of the VELO3D end-to-end manufacturing solution for serial production,” says Benny Buller, founder and CEO of VELO3D. “Assure is part of our vision to provide an integrated solution to produce parts by additive manufacturing with successful outcomes.”
Stratasys Direct began working with VELO3D on Assure testing soon after they acquired a Sapphire printer earlier in the year. Stratasys Direct implemented Assure to identify variations and anomalies in the production of the parts on several builds. Throughout the study, Stratasys Direct accessed Assure’s dashboard and sophisticated algorithms to monitor the integrity of the builds, validate the bulk material density, observe ongoing process metrics, and verify the calibration of the system across multiple production runs. These trials and results confirmed the capabilities of the software, and were documented in a whitepaper that both VELO3D and Stratasys Direct co-authored which can be downloaded at https://info.stratasysdirect.com/rs/626-SBR-192/images/VELO3D_ASSURE_White_Paper_201911.pdf?utm_source=pr&utm_medium=release&utm_campaign=WEBREC-2019-WP-VELO3D-ASSURE
“Stratasys Direct has built a culture of continuous improvement that means we are continually setting new standards for our industry on quality,” said Kent Firestone, CEO of Stratasys Direct Manufacturing. “We integrated Assure into our quality control workflow because it produces highly actionable insights. The user interface features intuitive graphs and charts that enable us to see and interpret the vast amount of data collected during builds. This information helps our engineers verify the quality of the build each step of the way, and enables them to make quick decisions in the event of an issue. Assure helps us reduce production variation, improve yields, and circumvent anomalies to ensure consistent additive manufacturing.”
To learn more about Assure:
-
Stratasys Direct will host a webinar on November 14th at 10am PST; please visit this link to register:
https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=&eventid=2126421&sessionid=1&key=3925B221E06F51D08CE47106E3AD4F54®Tag=&sourcepage=register - VELO3D and Stratasys Direct will host a joint press conference at the VELO3D booth (Hall 11, E79) at formnext in Frankfurt, Germany on November 19 at 10 a.m.
About VELO3D
VELO3D empowers companies to manufacture anything. By bringing together innovations in software, hardware, and process control, VELO3D created the industry’s first SupportFree solution for 3D metal printing, enabling unlimited design innovation by reducing the need for support structures in metal additive manufacturing. The company’s Sapphire® system is built with a semiconductor mindset on quality assurance, ensuring repeatability and dependability throughout serial manufacturing. Headquartered in Silicon Valley, VELO3D helps companies deliver immediate business impact by making the impossible, possible. To learn more, please visit www.velo3D.com.
About Stratasys Direct
Stratasys Direct Manufacturing Inc. is the leading provider of 3D printing and advanced manufacturing services utilizing a broad range of additive and conventional technologies. We leverage nearly 30 years of 3D printing, design and engineering experience to ensure customers’ project success in each stage of product development, from prototypes to production runs. Serving companies of all sizes, from start-ups to established global brands, we develop methods, materials and processes that optimize and enhance additive and conventional manufacturing’s capabilities. Online at: www.stratasysdirect.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005695/en/
Contact information
VELO3D
Joyce Yeung
joyce.yeung@velo3D.com
972.914.8732
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom